Patents by Inventor Roshantha A. Chandraratna

Roshantha A. Chandraratna has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Autoimmune disorder treatment using RXR agonists
    Patent number: 10285960
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: May 14, 2019
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
    Patent number: 10278932
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: May 7, 2019
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • AUTOIMMUNE DISORDER TREATMENT USING RXR AGONISTS
    Publication number: 20190125705
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Application
    Filed: December 20, 2018
    Publication date: May 2, 2019
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • TREATMENT OF CANCER WITH SPECIFIC RXR AGONISTS
    Publication number: 20190117603
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Application
    Filed: December 17, 2018
    Publication date: April 25, 2019
    Inventor: Roshantha A. Chandraratna
  • RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY
    Publication number: 20190105292
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Application
    Filed: December 5, 2018
    Publication date: April 11, 2019
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS
    Publication number: 20190083441
    Abstract: The present specification provides methods of treating disease with an ester of an RXR agonist or a combination of an ester of an RXR agonist and a thyroid hormone. The esters of an RXR agonist can be useful in the treatment of cancer, nervous system, autoimmune, and muscular disorders.
    Type: Application
    Filed: September 20, 2018
    Publication date: March 21, 2019
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
    Patent number: 10231944
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: March 19, 2019
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • RAR SELECTIVE AGONISTS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY
    Publication number: 20190060362
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
    Type: Application
    Filed: August 30, 2018
    Publication date: February 28, 2019
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
    Patent number: 10213401
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: February 26, 2019
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Autoimmune disorder treatment using RXR agonists
    Patent number: 10201512
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: February 12, 2019
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle
  • Treatment of cancer with specific RXR agonists
    Patent number: 10188618
    Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: January 29, 2019
    Assignee: IO Therapeutics, Inc.
    Inventor: Roshantha A. Chandraratna
  • RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY
    Publication number: 20190015363
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
    Type: Application
    Filed: July 12, 2018
    Publication date: January 17, 2019
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES
    Publication number: 20180369181
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Application
    Filed: August 30, 2018
    Publication date: December 27, 2018
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY
    Publication number: 20180338941
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Application
    Filed: July 31, 2018
    Publication date: November 29, 2018
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • IMMUNOMODULATORY AND DIFFERENTIATING FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY
    Publication number: 20180338940
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
    Type: Application
    Filed: July 12, 2018
    Publication date: November 29, 2018
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • USE OF CYP26-RESISTANT RAR ALPHA SELECTIVE AGONISTS IN THE TREATMENT OF CANCER
    Publication number: 20180333380
    Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
    Type: Application
    Filed: November 23, 2016
    Publication date: November 22, 2018
    Inventors: Gabriel Ghiaur, Richard J. Jones, Alonso Salvador, Roshantha A. Chandraratna
  • Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
    Patent number: 10123982
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: November 13, 2018
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • TREATMENT OF NERVOUS SYSTEM DISORDERS USING THYROID HORMONE NEUTRAL DOSES OF RXR AGONISTS
    Publication number: 20180318241
    Abstract: The present specification provides methods of treating nervous system disorders with a thyroid hormone neutral dose of a RXR agonist to promote remyelination or neuroprotection or both and thereby maintain or regenerate healthy axons and neurons.
    Type: Application
    Filed: October 31, 2016
    Publication date: November 8, 2018
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
    Patent number: 10092535
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: October 9, 2018
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • AUTOIMMUNE DISORDER TREATMENT USING RXR AGONISTS
    Publication number: 20180263939
    Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.
    Type: Application
    Filed: May 24, 2018
    Publication date: September 20, 2018
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle